Table 2.
Result of serum CGA level
| Characteristics | pNET | PC | CP | AIP | Normal |
|---|---|---|---|---|---|
| Total | |||||
| Number | 69 | 50 | 50 | 20 | 112 |
| CGA level (ng/mL) | |||||
| Mean ± SD | 407.8 ± 984.6* | 91.8 ± 101.8† | 93.6 ± 57.5† | 69.9 ± 52.4 | 62.5 ± 48.3 |
| PPI use (%) | |||||
| Yes | |||||
| Number | 19 (27.5) | 19 (38.0) | 28 (56.0) | 9 (45.0) | N/A |
| CGA level (ng/mL) | |||||
| Mean ± SD | 297.7 ± 389.1 | 155.9 ± 129.8‡ | 107.6 ± 66.9‡ | 98.5 ± 64.2‡ | |
| No (%) | |||||
| Number | 50 (72.5) | 31 (62.0) | 22 (44.0) | 11 (55.0) | 112 (100) |
| CGA level (ng/mL) | |||||
| Mean ± SD | 449.6 ± 1132.8* | 52.5 ± 51.2* | 75.7 ± 37.1 | 46.6 ± 24.1 | 62.5 ± 48.3 |
Significant difference between each group was evaluated by Scheffe's multiple comparison.
*
P < 0.01 versus normal.
†
P < 0.05 versus pNET. Significant difference between with or without PPI use in the same group was evaluated by Student t-test.;
‡
P < 0.05 versus no PPI use. AIP, autoimmune pancreatitis; CGA, chromogranin A; CP, chronic pancreatitis; PC, pancreatic cancer; pNET, pancreatic neuroendocrine tumor; PPI, proton pump inhibitor.